Loading...
By Kristin J. Kelley
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
The labels of sodium-glucose co-transporter 2 (SGLT2) inhibitors — drugs used to treat type 2 diabetes — will be updated to warn of the risks for ketoacidosis and serious urinary tract infections, the FDA announced on Friday.
Updating a May 2015 safety communication, the FDA says 73 cases of diabetic ketoacidosis and 19 cases of urosepsis and pyelonephritis (that began as UTIs) have been reported in patients taking the drugs. All patients needed to be hospitalized or treated in the emergency department.
Clinicians should evaluate patients taking SGLT2 inhibitors for ketoacidosis if they present with associated symptoms (e.g., abdominal pain, vomiting), the FDA advises, noting that ketoacidosis can occur even if blood glucose levels aren't particularly high. If ketoacidosis is suspected, the SGLT2 inhibitor should be stopped and the complication treated immediately. Similarly, UTIs should be treated promptly.
Manufacturers of SGLT2 inhibitors, which include canagliflozin, dapagliflozin, and empagliflozin, are now required to perform postmarketing safety studies for 5 years.
Comment
LINK(S):
FDA MedWatch safety alert (Free)
FDA drug safety communication (Free)
Background: NEJM Journal Watch General Medicine coverage of SGLT2 inhibitor adverse effects (Your NEJM Journal Watch subscription required)
Background: Physician's First Watch coverage of May 2015 warning (Free)